Last reviewed · How we verify

NCT04829227

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

Completed Phase 3 Last updated 26 October 2022
What this trial tests

Phase 3 trial testing Sofwave in Skin Laxity in 45 participants. Completed in 31 December 2021.

Timeline
10 January 2020
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorSofwave Medical LTD
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingsingle
Primary purposetreatment
Enrollment45
Start date10 January 2020
Primary completion31 December 2021
Estimated completion31 December 2021
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Sofwave Medical LTD

Who can join

Adults 35 to 80, any sex, with Skin Laxity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, non-randomized 2 arms prospective, multi-center, self-controlled clinical study with masked evaluation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sofwave

Trials testing the same drug.

Other recruiting trials for Skin Laxity

Currently open trials in the same condition.

Other Sofwave Medical LTD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing